21 September 2021

Anjarium Biosciences AG, a biotech company in Schlieren (ZH) focused on creating and delivering a new class of non-viral gene therapies has closed a CHF55.5m (USD 61m) Series A Financing. The round was co-led by Abingworth and Gimv, with significant participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic disease throughout a patient’s lifetime. The Company’s versatile platform – including its novel HybridosomeTM technology – aims to leverage breakthrough science and expertise at the interface of genetic medicine, synthetic biology and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies.

VISCHER is advising Anjarium with Matthias Staehelin and Pauline Pfirter (both Coporate/M&A).

Press release

Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk

You are currently offline. Some pages or content may fail to load.